摘要
目的 探讨胰激肽原酶肠溶片治疗糖尿病视网膜病变（diabetic retinopathy,DR）患者的效果及对视盘及黄斑部视网膜血流动力学的影响。方法 86例（140眼）DR患者,采用随机数字表法分为胰激肽原酶组和常规组各43例,2组均采用基础性疗法,胰激肽原酶组同时加用胰激肽原酶治疗,对比2组最佳矫正视力、临床效果及视盘及黄斑部视网膜血流动力学变化。结果 治疗后,胰激肽原酶组的最佳矫正视力（best corrected visual acuity,BCVA）值大于常规组（P〈0.05）,胰激肽原酶组的视网膜新生血管荧光素渗漏面积小于常规组（P〈0.05）,胰激肽原酶组视盘大血管及黄斑部视网膜的血流量、血流速度测定值均大于常规组,胰激肽原酶组的临床疗效优于常规组（P〈0.05）。结论 胰激肽原酶肠溶片治疗DR患者有利于改善视盘及黄斑部视网膜血流参数、提升患者视力、减少视网膜新生血管荧光素渗漏面积,从而提高临床治疗效果。
Objective To explore the pancreatic kininogenase enteric-coated tablets in the treatment of diabetic retinopathy （DR） patients and its effect on the optic disc and macula retinal hemodynamics. Methods 86 cases （140 eyes） of DR patients were randomly divided into pancreatic kininogenase group and normal group with 43 cases in each group, two groups were treated with basic therapy, pancreatic kininogenase group were combined with pancreatic kininogenase treatment. The best corrected visual acuity and the clinical effect of optic disc and macula retinal hemodynamic changes were compared between two groups. Results After treatment, the best corrected visual acuity （BCVA） in pancreatic kimnogenase group was greater than the normal group （P〈0.05）, the retinal neovascularization and fluorescein leakage area in pancreatic kininogenase group was less than the normal group （P〈0.05）. The disc vascular and macular retinal blood flow volume （VOL）, blood flow velocity （FLW）values in pancreatic kininogenase group were larger than those of normal group, and the clinical curative effect of pancreatic kininogenase group was better than that of normal group （P〈0.05）. Conclusion Pancreatic kminogenase enteric-coated tablets in the treatment of DR patients can improve the optic disc and macular retinal hemodynamic parameters, improve visual acuity and reduce the retinal neovascularization and fluorescein leakage area, so as to improve the clinical treatment effect.
出处
《中国生化药物杂志》
CAS
2017年第1期154-156,共3页
Chinese Journal of Biochemical Pharmaceutics
